Absci's ABS-201 Shows Favorable Safety in Trial, Cash Runway Extended to H1 2028
ABSI sits 40% above its 52-week low of $2.01.
Summary
Absci Corporation announced positive updates for its lead therapeutic candidate, ABS-201, reporting favorable emerging safety data from the first three dosed cohorts in its Phase 1/2a HEADLINE trial for androgenetic alopecia. The company also unveiled promising human ex vivo data demonstrating ABS-201's ability to stimulate hair growth and regenerate follicle stem cells. Financially, Absci reported sufficient cash, cash equivalents, and marketable securities to fund operations into the first half of 2028, significantly extending its runway. Additionally, the company appointed Ransi Somaratne, M.D., FACC, MBA, as its new Chief Medical Officer. These updates are highly material for a clinical-stage biotech, de-risking its lead asset and providing crucial financial stability. Investors will now watch for preliminary safety and PK data in the first half of 2026 and interim proof-of-concept data in the second half of 2026, along with the planned initiation of a Phase 2 trial for endometriosis in Q4 2026.
At the time of this announcement, ABSI was trading at $2.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $452.6M. The 52-week trading range was $2.01 to $5.23. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.